Reveal LINQ vs Tempus ECG-Low EF
AI Verdict
Choose Reveal LINQ if…
Choose Reveal LINQ if you require long-term, continuous cardiac monitoring to diagnose infrequent or unexplained arrhythmias, such as those associated with cryptogenic stroke or syncope, over an extended period of up to three years. Its implantable nature and AI-powered detection are ideal for capturing transient events that might be missed by shorter-term monitoring solutions.
View Reveal LINQ →Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if you need an AI-powered software solution to quickly screen 12-lead ECGs for signs of low left ventricular ejection fraction in patients 40 years or older at risk of heart failure. This tool is best suited for aiding clinicians in identifying patients who may require further evaluation for heart failure within a standard clinical diagnostic workflow.
View Tempus ECG-Low EF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Reveal LINQ | Tempus ECG-Low EF |
|---|---|---|
| Deployment | The Reveal LINQ ICM is an implantable device placed just beneath the skin in the upper left side of the chest through a small incision. The system includes a MyCareLink™ Monitor, a bedside unit that collects data from the ICM and sends it to the doctor. The Reveal LINQ Mobile Manager app, used by healthcare professionals, is downloaded to an iPad or Android tablet and paired via Bluetooth to a Medtronic patient connector, which communicates with the ICMs. | Integrates with current ECG platforms and electronic health records (EHRs). |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-Low EFTempus ECG-Low EF (Tool B) integrates directly into existing 12-lead ECG workflows, making its adoption and use by clinicians potentially more seamless as it leverages familiar diagnostic procedures. Reveal LINQ (Tool A), while offering patient convenience post-implantation, requires a surgical procedure and a dedicated device management ecosystem for clinicians.
Clinical Value
Reveal LINQReveal LINQ (Tool A) offers continuous, long-term ECG monitoring for up to three years, providing definitive diagnostic data for intermittent arrhythmias that are often missed by single-point tests. Its AccuRhythmu2122 AI algorithms further enhance diagnostic accuracy by reducing false alerts. Tempus ECG-Low EF (Tool B), while valuable, serves primarily as a screening tool to prompt further evaluation.
Pricing & Value
TieBoth tools lack public pricing information, making a direct comparison of their cost-effectiveness impossible. While both offer significant clinical value in their respective domains, their distinct deployment models (implantable device vs. software) imply different cost structures and value propositions that cannot be quantified without specific pricing details.
Enterprise Readiness
Reveal LINQMedtronic (Tool A's company), as a global leader in medical devices, possesses a vast and established infrastructure for sales, support, and integration of complex medical technologies within healthcare systems. While Tempus AI (Tool B's company) is strong in software integration and compliance, Medtronic's long-standing presence and comprehensive ecosystem for implantable devices likely provide a more robust foundation for enterprise-level deployment and support.
Innovation
Reveal LINQReveal LINQ (Tool A) demonstrates innovation across both hardware and software, combining the world's smallest insertable cardiac monitor with long-term continuous monitoring, MRI compatibility, and AI algorithms to reduce false alerts. Tempus ECG-Low EF (Tool B) innovates by applying AI to existing ECGs to derive new diagnostic insights, but Reveal LINQ's multi-faceted advancements in device technology and AI for continuous monitoring are arguably more comprehensive.
Support & Docs
Reveal LINQMedtronic (Tool A's company), as a large and established medical device company, is expected to have a comprehensive and mature support infrastructure, including technical assistance, field representatives, and extensive documentation for its complex implantable devices and associated systems like the CareLinku2122 network. While Tempus AI (Tool B's company) would also offer support, Medtronic's scale and long history in the medical device sector suggest a more extensive and proven support ecosystem.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Reveal LINQ | Tempus ECG-Low EF |
|---|---|---|
| Name | Reveal LINQ | Tempus ECG-Low EF |
| Company | Medtronic | Tempus AI |
| Core Function / What it detects | Continuously records ECG for up to three years, utilizing AccuRhythmu2122 AI algorithms to accurately detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope. | Analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%). |
| Key Technology / Algorithm | AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause). | AI-powered algorithm for ECG analysis, trained on a large dataset of over 930,000 ECGs from 170,000+ patients. |
| Target Patient Population/Use Case | Patients needing continuous ECG monitoring for cardiac arrhythmias, cryptogenic stroke, and unexplained syncope. | Patients 40 years or older at risk of heart failure, for use in clinical diagnostic settings at healthcare facilities. |
| Monitoring Duration / Input Type | Continuous ECG monitoring for up to three years (implantable device). | Analyzes resting, non-ambulatory 12-lead ECG recordings. |
Videos
Demos, reviews, and walkthroughs featuring Reveal LINQ and Tempus ECG-Low EF.